GlassScriptPhysician profile
Laura J Tibbe
NPI 1356310379
$3,721.04
in general payments reported to CMS, 2019-2025
37 companies · $639 in 2025
The $639 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $180 · 2021: $319 · 2022: $572 · 2023: $796 · 2024: $912 · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,298 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,297.79 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $671.04 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $385.81 | 2019-2025 | Rybelsus, Ozempic |
| Abbott Laboratories | $283.39 | 2021-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Lilly USA, LLC | $214.31 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $190.96 | 2022-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $188.92 | 2019-2025 | Bevespi Aerosphere |
| Bayer Healthcare Pharmaceuticals INC. | $178.22 | 2022-2025 | |
| Allergan, INC. | $162.39 | 2019-2020 | |
| Glaxosmithkline, LLC. | $144.52 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $144.22 | 2023-2025 | Otezla, Repatha, Prolia |
| Pfizer INC. | $119.57 | 2020-2025 | |
| Ironshore Pharmaceuticals INC. | $88.57 | 2019-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $86.85 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Xeris Pharmaceuticals, INC. | $77.98 | 2023-2024 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $66.40 | 2024 | Voquezna |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Tibbe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.